European Genomics & Sequencing 2026: NGS, CRISPR, NIPT, Single-Cell

The Estonian Genome Center (Tartu) is the directory’s European population-genomics entry. Part of the University of Tartu, the EGC runs the Estonian Biobank — one of Europe’s largest population-scale genomic data collections with public-good research access under Estonian law and aligned with the European Health Data Space (EHDS) secondary-use framework (see the EU Biotech Regulation 2026 brief). Around EGC, Tartu concentrates a genomics + biotech cluster: Asper Biogene runs genetic testing + NGS services + clinical diagnostic panels; Antegenes runs polygenic risk testing + cancer-prevention diagnostics + medical genetics services; Arpengen runs DNA + RNA extraction kits; Biocad EU Research runs genomics research services. Together the Tartu genomics cluster is the directory’s Baltic population-genomics entry point.

Vilnius hosts 5 directory-listed genomics operators — the highest Baltic single-city genomics operator count in the directory. CasZyme operates CRISPR-Cas technology with commercialised IP originating at Vilnius University (CRISPR-Cas9 research was developed in Lithuanian labs in parallel with the Doudna/Charpentier work). Droplet Genomics runs single-cell analysis + microfluidics + droplet technology + sequencing preparation tools. Atrandi Biosciences runs single-cell analysis platforms. Saidė Genomics runs NIPT + clinical NGS + sequencing services + pharmacogenomics + cancer testing. Gensinta runs synthetic biology + photonics-based DNA synthesis + next-generation genomics tools. Combined with CasZyme’s CRISPR platform, this cluster gives the directory a concentrated Vilnius genomics-innovation layer across single-cell, CRISPR, NGS, and synthesis modalities.

Clinical NGS + genetic diagnostics concentrate at 7 directory operators. CeGaT (Tübingen, Germany) runs clinical NGS diagnostics + whole-exome + whole-genome sequencing + genomic research services. Blueprint Genetics (Espoo, Finland) runs rare-disease genetic testing + genomic diagnostics + clinical interpretation (part of the Quest Diagnostics group). Asper Biogene (Tartu) covers Estonian NGS + clinical diagnostic panels. Genomed (Warsaw, Poland) runs genomics + DNA sequencing + RNA analysis + genetic diagnostics. 4bases (Manno, Switzerland) runs CE-IVD NGS reagent kits + genetic diagnostic protocols + clinical sequencing pipelines. GenEra (Riga, Latvia) covers medical DNA testing + NIPT + kinship testing + NGS + genetic diagnostics. Saidė Genomics (Vilnius) covers NIPT + sequencing + pharmacogenomics. For sponsors running clinical-diagnostic NGS or rare-disease testing programmes, these seven operators cover the European clinical-NGS layer.

Non-invasive prenatal testing (NIPT) runs through GenEra (Riga), Saidė Genomics (Vilnius), and Blueprint Genetics (Espoo, rare-disease focus includes prenatal). Reproductive-health diagnostics broadens through Vitrolife Group (Gothenburg, Sweden) which covers IVF media + reproductive diagnostics at commercial scope. For sponsors running NIPT service partnerships or reproductive-genetic programmes, this is the directory-visible European layer.

The European genomics research layer the directory surfaces anchors at two German institutions. EMBL Heidelberg runs molecular biology + genomics + structural biology as a pan-European research infrastructure. Max Delbrück Center (Berlin-Buch) runs biomedical research + genomics + cell engineering + translational technology platforms. For genomics tools + extraction + synthesis, the directory adds Arpengen (Tartu, DNA/RNA kits), Gensinta (Vilnius, DNA synthesis), PentaBase (Odense, qPCR + oligos), 4bases (Manno, NGS kits). Broader molecular-diagnostics tooling routes through QIAGEN (Hilden, Germany) — covered in the European Diagnostics Landscape 2026 brief as the pan-European molecular-diagnostics anchor.

Adjacent genomics + sequencing modalities the directory covers include: Age Labs (Oslo, Norway, epigenetic DNA-methylation biomarkers + early-disease detection), Spindiag (Freiburg, point-of-care multiplex PCR + centrifugal microfluidics), Memo Therapeutics (Schlieren, DROPZYLLA microfluidic antibody discovery using genomics-scale sequencing readouts), Arctic Bioscience (Orsta, marine-lipid + genomic research adjunct). These adjacent operators sit at the discovery + clinical-stage layer rather than primary sequencing services, but cover specific modalities relevant to genomics sponsors.

European genomics regulation runs through three overlapping regimes in 2026. The European Health Data Space (EHDS, entering application 2026–2029) governs secondary use of health data including genomic data, with national Health Data Access Bodies coordinating research-access workflows. The EU In Vitro Diagnostic Regulation (IVDR) covers CE-IVD NGS kits (like 4bases) and clinical diagnostic panels (Asper Biogene, CeGaT, Blueprint Genetics) — Class C high-risk devices reached full IVDR application over 2026–2027. The AI Act (Article 6(1)) applies to AI-assisted genomics diagnostic systems embedded in MDR/IVDR devices from August 2027. GDPR Article 9 governs genetic data as a special category. For sponsors running European genomics programmes, regulatory clearance involves coordinating across EHDS, IVDR, AI Act, and GDPR. The EU Biotech Regulation 2026 brief covers the full regulatory context.